Inventor · disambiguated record
Peter Kufer
Also filed as: KUFER PETER
65 granted patents·46 pending applications·1,725 citations·filing 1998–2025
99Inventor score
Top patents by PatentIndex Score
111 records- 0198US9340621B2Binding molecules for BCMA and CD3AMGEN RES MUNICH GMBH·Filed 2012·Granted May 17, 2016·91 cites·15 claims
- 0297US10294300B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted May 21, 2019·37 cites·16 claims
- 0397US9150664B2Binding molecules for BCMA and CD3AMGEN RES MUNICH GMBH·Filed 2012·Granted Oct 6, 2015·64 cites·15 claims
- 0497US7235641B2Bispecific antibodiesMICROMET AG·Filed 2003·Granted Jun 26, 2007·167 cites·2 claims
- 0596US11591396B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2020·Granted Feb 28, 2023·5 cites·33 claims
- 0696US8007796B2Means and methods for the treatment of tumorous diseasesMICROMET AG·Filed 2006·Granted Aug 30, 2011·69 cites·18 claims
- 0796US7635472B2Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disordersMICROMET AG·Filed 2004·Granted Dec 22, 2009·158 cites·8 claims
- 0895US11472886B2Cross-species-specific PSMAxCD3 bispecific single chain antibodyAMGEN RES MUNICH GMBH·Filed 2021·Granted Oct 18, 2022·3 cites·13 claims
- 0995US10301391B2BCMA and CD3 bispecific T cell engaging antibody constructsAMGEN RES MUNICH GMBH·Filed 2017·Granted May 28, 2019·28 cites·19 claims
- 1095US8236308B2Composition comprising cross-species-specific antibodies and uses thereofKISCHEL ROMAN·Filed 2006·Granted Aug 7, 2012·238 cites·9 claims
- 1195US7575923B2CD19xCD3 specific polypeptides and uses thereofMICROMET AG·Filed 2006·Granted Aug 18, 2009·103 cites·4 claims
- 1294US9765157B2Antibody constructs for CDH19 and CD3AMGEN INC·Filed 2015·Granted Sep 19, 2017·13 cites·14 claims
- 1394US9598500B2Binding molecules for BCMA and CD3AMGEN RES MUNICH GMBH·Filed 2012·Granted Mar 21, 2017·22 cites·15 claims
- 1494US7632925B2Antibodies that bind human 17-A1/EpCAM tumor antigenMICROMET AG·Filed 2007·Granted Dec 15, 2009·17 cites·10 claims
- 1594US7112324B1CD 19×CD3 specific polypeptides and uses thereofMICROMET AG·Filed 1999·Granted Sep 26, 2006·219 cites·23 claims
- 1693US10683351B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2019·Granted Jun 16, 2020·4 cites·24 claims
- 1793US10519241B2Antibody constructs for EGFRVIII and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Dec 31, 2019·16 cites·22 claims
- 1893US8101722B2Less immunogenic binding moleculesKUFER PETER·Filed 2005·Granted Jan 24, 2012·37 cites·23 claims
- 1992US10781264B2PSMA and CD3 bispecific T cell engaging antibody constructsAMGEN RES MUNICH GMBH·Filed 2017·Granted Sep 22, 2020·8 cites·22 claims
- 2092US10766969B2Binding molecules for BCMA and CD3AMGEN RES MUNICH GMBH·Filed 2012·Granted Sep 8, 2020·8 cites·29 claims
- 2192US9982063B2Pharmaceutical compositions with resistance to soluble CEAAMGEN RES MUNICH GMBH·Filed 2016·Granted May 29, 2018·14 cites·25 claims
- 2292US8784821B1Human-anti-human cd3 binding moleculesKUFER PETER·Filed 2004·Granted Jul 22, 2014·63 cites·23 claims
- 2392US7919089B2Pharmaceutical composition comprising a bispecific antibody for EpCAMMICROMET AG·Filed 2004·Granted Apr 5, 2011·57 cites·3 claims
- 2491US11434302B2Bispecific T cell engaging antibody constructsAMGEN RES MUNICH GMBH·Filed 2017·Granted Sep 6, 2022·7 cites·19 claims
- 2591US8840888B2Dosage regimen for administering a CD19XCD3 bispecific antibodyNAGORSEN DIRK·Filed 2010·Granted Sep 23, 2014·23 cites·34 claims
- 2690US12281176B2Binding molecules for BCMA and CD3AMGEN INC·Filed 2021·Granted Apr 22, 2025·1 cites·7 claims
- 2790US10752694B2Binding molecules for BCMA and CD3AMGEN RES MUNICH GMBH·Filed 2014·Granted Aug 25, 2020·11 cites·15 claims
- 2890US9688760B2Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domainsAMGEN RES MUNICH GMBH·Filed 2014·Granted Jun 27, 2017·17 cites·10 claims
- 2990US9587036B2Cross-species-specific PSMAxCD3 bispecific single chain antibodyKUFER PETER·Filed 2011·Granted Mar 7, 2017·24 cites·34 claims
- 3089US11084876B2Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domainsAMGEN RES MUNICH GMBH·Filed 2017·Granted Aug 10, 2021·4 cites·14 claims
- 3189US10662243B2Dosage regimen for administering a CD19XCD3 bispecific antibodyAMGEN RES MUNICH GMBH·Filed 2014·Granted May 26, 2020·6 cites·20 claims
- 3288US11987633B2Cross-species-specific single domain bispecific single chain antibodyAMGEN RES MUNICH GMBH·Filed 2021·Granted May 21, 2024·1 cites·27 claims
- 3388US9260522B2Bispecific single chain antibodies with specificity for high molecular weight target antigensKUFER PETER·Filed 2009·Granted Feb 16, 2016·7 cites·4 claims
- 3487US11661462B2Optimized cross-species specific bispecific single chain antibody contructsAMGEN RES MUNICH GMBH·Filed 2015·Granted May 30, 2023·4 cites·12 claims
- 3587US10059766B2Antibody constructs for CDH19 and CD3AMGEN RES MUNICH GMBH·Filed 2014·Granted Aug 28, 2018·9 cites·17 claims
- 3687US8394926B2Pharmaceutical compositions with resistance to soluble CEALUTTERBUESE RALF·Filed 2006·Granted Mar 12, 2013·21 cites·34 claims
- 3786US11155629B2Method for treating glioblastoma or glioma with antibody constructs for EGFRVIII and CD3AMGEN RES MUNICH GMBH·Filed 2019·Granted Oct 26, 2021·2 cites·20 claims
- 3886US8790645B2Pharmaceutical composition comprising a bispecific antibody for EpCAMKUFER PETER·Filed 2011·Granted Jul 29, 2014·10 cites·13 claims
- 3985US10981998B2Cross-species-specific single domain bispecific single chain antibodyKUFER PETER·Filed 2009·Granted Apr 20, 2021·5 cites·18 claims
- 4084US12435139B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2022·Granted Oct 7, 2025·0 cites·12 claims
- 4184US11352433B2BCMA and CD3 bispecific T cell engaging antibody constructsAMGEN RES MUNICH GMBH·Filed 2019·Granted Jun 7, 2022·2 cites·23 claims
- 4283US10047159B2Bispecific single chain antibodies with specificity for high molecular weight target antigensAMGEN RES MUNICH GMBH·Filed 2016·Granted Aug 14, 2018·3 cites·18 claims
- 4383US2025064927A1Compositions comprising cross-species-specific antibodies and uses thereofAMGEN RES MUNICH GMBH·Filed 2024·Application pending·0 cites
- 4483US2025340639A1Antibody constructs for dll3 and cd3AMGEN RES MUNICH GMBH·Filed 2025·Application pending·0 cites
- 4582US12297292B2Antibody constructs for CDH19 and CD3AMGEN INC·Filed 2017·Granted May 13, 2025·2 cites·12 claims
- 4682US7435549B1Method of identifying binding site domains that retain the capacity of binding to an epitopeMICROMET AG·Filed 1998·Granted Oct 14, 2008·51 cites·47 claims
- 4782US7227002B1Human antibodies that bind human 17-A1/EpCAM tumor antigenMICROMET AG·Filed 1998·Granted Jun 5, 2007·52 cites·10 claims
- 4881US2022251243A1Binding molecules for bcma and cd3AMGEN INC·Filed 2022·Application pending·0 cites
- 4980US11154617B2Means and methods for the treament of B cell non-hodgkin lymphoma and B cell leukemiaBAEUERLE PATRICK·Filed 2011·Granted Oct 26, 2021·4 cites·10 claims
- 5080US9695250B2Pharmaceutical compositions with resistance to soluble CEAAMGEN RES MUNICH GMBH·Filed 2013·Granted Jul 4, 2017·4 cites·19 claims
Showing the top 50 of 111 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Peter Kufer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →